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BAckground: Multiple sclerosis (MS) is a chronic and debilitating disease of the 
central nervous system that affects approximately 570,000 persons in the United 
States and 2.3 million worldwide. As most individuals experience initial symptoms 
between the ages of 20 and 40 years, MS can have a significant impact on health-
care consumption, productivity and employment. oBjectives: To compare the 
work productivity impairment in patients initiated on delayed-release dimethyl 
fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon 
β -1a/b or glatiramer acetate (ABCRE) therapies. Methods: Data were identified 
from the Adelphi MS Disease Specific Programme, a cross-sectional study of MS 
patients in five EU countries and US. Relapsing Remitting MS (RRMS) patients were 
identified, receiving DMF or ABCRE therapies with treatment duration greater than 
12 months. Inverse-probability-weighted regression-adjustment estimated aver-
age treatment effects (ATEs) across DMF and ABCRE cohorts, utilizing a propensity 
score generated from age, gender, EDSS score at current treatment initiation, BMI, 
duration of current treatment, line of therapy, time since MS diagnosis, and num-
ber of comorbid conditions. Work productivity and daily activity impairment due 
to MS, as measured by the Work Productivity and Activity Impairment (WPAI:MS) 
questionnaire, were compared across treatment arms. results: Work productivity 
and activity impairment data was available for 160 and 243 patients, respectively. 
Overall work impairment due to MS was significantly lower in the DMF cohort 
(ATE= -13.92%, p< 0.001, vs. 20.92%). Similarly, impairment while working (presentee-
ism) due to MS was significantly lower in the DMF cohort (ATE= -12.97%, p< 0.001, vs. 
19.45%). No percent of work missed (absenteeism) was observed in the DMF cohort 
(ATE= -2.06%, p= 0.012, vs. 2.06%). Daily activity impairment was significantly lower 
in the DMF cohort (ATE= -17.26%, p< 0.001, vs. 25.31%). conclusions: Compared 
with ABCRE patients, patients on DMF had a significantly lower work productivity 
loss as measured by WPAI-MS.
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oBjectives: MS is a chronic disease associated with substantial clinical and socio-
economic burden. MS patients experience increasing levels of disability as their 
disease progresses. This study investigates the association between increasing MS 
severity and its impact on relapsing-remitting (RRMS) and secondary progressive 
(SPMS) MS patients. Methods: Data were drawn from the Adelphi MS Disease 
Specific Programme, a global (France, Germany, Italy, Spain, UK, USA) cross-sectional 
study with 2965 RRMS and 494 SPMS patients. Multiple logistic, linear and partial 
proportional odds regressions determined the association between physician-
reported MS severity (‘very mild’ [RRMS only], ‘mild’, ‘moderate’, ‘severe’) and pres-
ence of an informal caregiver, weekly informal caregiver hours, and employment 
status, respectively. Regressions adjusted for age, gender, BMI and number of con-
comitant conditions. Reference category was ‘very mild’ and ‘mild’ for RRMS and 
SPMS, respectively. results: For RRMS patients, the likelihood of part-time employ-
ment or unemployment, increased with MS severity (mild: OR = 1.51; moderate: OR = 
3.28; severe: OR = 17.39; p< 0.001 for all) and (mild: OR = 1.18, p= 0.143; moderate: OR = 
2.45, p< 0.001; severe: OR = 8.53, p< 0.001), respectively. Similar results were observed 
in SPMS patients (moderate: OR = 3.41, p= 0.002; severe: OR = 16.85, p< 0.001) and 
(moderate: OR = 3.41, p= 0.002; severe: OR = 16.85, p< 0.001). Increasing level of sever-
ity was associated with a higher likelihood of informal care (RRMS: mild: OR = 1.60, 
p= 0.040; moderate: OR = 4.27, p< 0.001; severe: OR = 15.31, p< 0.001; SPMS: moderate: 
OR = 6.70, p< 0.001; severe: OR = 14.93, p< 0.001) and higher weekly informal car-
egiver hours (RRMS: mild: +0.97, p= 0.014; moderate: +4.52, p< 0.001; severe: +13.27, 
p< 0.001; SPMS: moderate: +8.45, p= 0.006; severe: +18.81, p< 0.001). conclusions: 
Increased MS severity is associated with significantly lower employment as well 
as increased caregiver burden. MS patients should start effective treatments early 
to delay disease progression.
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oBjectives: To compare resource utilization drivers of societal costs for 
Alzheimer’s disease (AD) over 18-months in three countries participating in 
an observational study. Methods: GERAS is a prospective, multi-centre, non-
interventional cohort study in France (n= 419), Germany (n= 550) and the UK 
(n= 526). Resource use of AD patients and caregivers (including informal car-
egiving time and institutionalization), contributing to > 1% total societal costs 
(comprising patient health and social care costs and informal caregiver costs 
- based on 2010 prices) were identified and assessed for country differences 
using Generalised Linear Models of repeated measures or Cox models, adjust-
ing for key patient and caregiver characteristics. results: 18-month societal 
costs per patient: France € 33,300, Germany € 38,200 and UK € 37,900. Caregiver 
time spent assisting patient with basic and instrumental activities of daily liv-
ing (ADL) made the largest contribution to total societal costs in each coun-
try (55-69%). Caregivers in France spent less time on basic and instrumental 
ADLs and were less likely to miss work. Patients in France used more commu-
nity care services and were more likely to spend time in respite care, whereas 
German patients were less likely to use respite care and had slower time to 
institutionalization (Hazard Ratio 0.59 (95% CI 0.41-0.84) Germany, 0.84 (0.60-1.18) 
France, reference UK; p-value 0.0143). UK caregivers spent more time on instru-
mental ADLs while patients used fewer outpatient resources but were more likely 
to receive financial support. No country differences in hospital stays or use of 
AD medication were seen. conclusions: Caregiver time was consistently the 
outcomes and costs was not conducted because the time horizon of the analysis 
did not exceed 1 year. Bivariate sensitivity analysis (SA) was performed. results: 
The cost of the 1st year therapy of compared drugs was: 28,822, 20,810, 57,449 
and 54,332 rubles for piribedil CR, pramipexole ER, ropinirole ER and rasagiline 
respectively. Total therapy cost was estimated by summarizing the cost of therapy 
and ADR costs. Total costs for comparator drugs constituted: 28,930, 21,009, 57,576 
and 54,381 rubles for piribedil CR, pramipexole ER, ropinirole ER and rasagiline 
respectively. Utility effect of the comparison drugs was: -6.1, -8.2, -0.3, -2.7 for 
piribedil CR, pramipexole ER, ropinirole ER and rasagiline respectively. In the 
analysis was found that pramipexole ER has the lowest cost-utility ratio (CUR) 
– 2,562 rubles for 1 point reduction of daytime activity disruption and severity 
of motor impairment as indicated by UPDRS scale. conclusions: Pramipexole 
ER has the lowest CUR. SA confirmed these results. Pramipexole ER was the 
dominant strategy for PD treatment demonstrating higher utility rate at lower 
costs.
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oBjectives: Incobotulinumtoxin-A is a formulation of botulinum neurotoxin type 
A (BoNT/A) that is free of complexing proteins. The advantages of incobotulinum-
toxin-A include flexible treatment intervals determined by clinical need. The objec-
tive of this study was to assess the cost-effectiveness of incobotulinumtoxin-A 
administered with flexible treatment intervals compared to onabotulinumtoxin-A 
in blepharospasm (BLEPH) and cervical dystonia (CD) from the Australian health-
care providers’ perspective. Methods: A Markov state transition model was 
developed to perform a cost-utility analysis (CUA) comparing the cost and health 
benefits of incobotulinumtoxin-A with onabotulinumtoxin-A. The CUA compared 
incobotulinumtoxin-A treatment, given at minimum intervals of 6 weeks and maxi-
mum intervals of 20 weeks, with onabotulinumtoxin-A treatment given at fixed 12 
week intervals. The Markov model consisted of three health states and followed 
patients in weekly cycles for one year. Only direct healthcare costs associated with 
the acquisition and administration of BoNT/A’s were included. Utility values were 
derived from a prospective, open-labelled cohort study. The primary outcome meas-
ure was the incremental cost per quality-adjusted life year (QALY). Univariate and 
probabilistic sensitivity analyses were conducted. results: Incobotulinumtoxin-A 
dominated onabotulinumtoxin-A in both BLEPH and CD. The option to administer 
incobotulinumtoxin-A according to patient needs resulted in patients experienc-
ing fewer number of weeks with symptoms compared to onabotulinumtoxin-A 
administered at fixed 12 week intervals. Incobotulinumtoxin-A provided cost 
savings to the Australian healthcare system. Results held under sensitivity analy-
ses. conclusions: Incobotulinumtoxin-A administered at flexible treatment 
intervals, determined by patient needs, represents a more cost-effective treatment 
option when compared with onabotulinumtoxin-A in the Australian healthcare 
system.
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oBjectives: A cohort Markov model based on disability scores was originally 
constructed. Due to constraints of a Markov structure and to test structural uncer-
tainty, a discrete event simulation (DES), based on time to event, was subsequently 
developed. Methods: The same inputs were used in both models, except that 
in the DES a cohort of individual patients that reflected the patients from the 
main fingolimod trials was used and risks of some events were linked to baseline 
characteristics. For both models, published post hoc clinical data in the HA RRMS 
subgroup were taken from the pivotal trials for fingolimod and DMF vs placebo. 
Utility data for each health state and for relapses were used in line with previous 
similar models. Published costs were inflated to NHS cost year 2013–14 and UK 
list prices used for both drugs. Possible Patient Access Scheme (PAS) discount sce-
narios were investigated. results: In the base case, using list prices, the average 
probabilistic incremental cost-effectiveness ratio (ICER) for fingolimod vs DMF 
was found to be £14,076 per QALY using the Markov model (incremental cost: 
£10,358, QALYs: 0.74) and £11,449 per QALY using the DES (incremental cost: £8,694, 
QALYs: 0.76), with a 73% and 72% chance of fingolimod being cost-effective at a 
willingness-to-pay threshold of £30,000/QALY, respectively. Both models were most 
sensitive to treatment effect on disability progression, but robust to other changes 
including incorporation of a wide range of PAS estimates. conclusions: The 
Markov and DES models produced similar results, both concluding that fingolimod 
remains cost-effective in HA RRMS following the introduction of DMF to the UK 
market. This validates the use of a DES in this situation. DES has greater potential 
than the Markov model to be easily adapted in the future to deal with changing 
assumptions on long-term efficacy, treatment sequences and chronic adverse 
events.
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daily living (T-IADL) in carers of patients with Alzheimer’s disease (AD). Methods: 
GERAS is a prospective, non-interventional cohort study in AD patients and caregiv-
ers. The Zarit Burden Inventory (ZBI) and the EQ-5D were used to measure burden 
and HRQoL respectively. Spearman correlations were computed between EQ-5D, ZBI 
and T-IADL at baseline, 18-months and for change over 18-months. T-IADL and ZBI 
change scores were summarised by EQ-5D domain change category (better/stable/
worse). results: 1495 caregivers were available at baseline [67 years (SD 12) and 
64% female]. According to baseline patient severity, caregivers’ EQ-5D health state 
values were 0.86, 0.85 and 0.82 and ZBI total scores were 25, 29 and 34 in mild, moder-
ate and moderately severe/severe AD respectively. T-IADL increased from a mean of 
79 hours (SD 89; median 60 hours) at baseline by a mean of 17 hours (SD 105; median 
10 hours) over 18-months, and showed a stronger correlation with ZBI than with 
EQ-5D, although correlations were low for both (e.g. change scores 0.118 ZBI; 0.020 
EQ-5D). Worsening within EQ-5D domains (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) was associated with the greatest increase in 
burden scores, although the majority of caregivers (68-90%) remained stable within 
each EQ-5D domain. Relative to these stable caregivers, larger increases in T-IADL 
over 18–months were associated with better ratings in mobility and usual activities 
but worsening in pain/discomfort. Larger increases in T-IADL were associated with 
both better and worse ratings in anxiety/depression [23.5 hours better (11%); 12.2 
hours stable (68%); 24.8 hours worse (16%)]. conclusions: EQ-5D health state 
values had low sensitivity to changes in caregiver time over an 18-month period. 
ZBI may better reflect the impact of caring for AD patients.
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oBjectives: This systematic literature review (SLR) aimed to identify health state 
utility values among migraine patients. Methods: A SLR was conducted in bio-
medical databases and Health Technology Assessment (HTA) websites from 2000-
2014. Search terms included different combinations of migraine along with utility 
or quality-of-life measures. References of identified SLR/meta-analyses were inves-
tigated to identify additional studies. Each study was reviewed by two independent 
reviewers; disagreements were resolved by a third reviewer. results: The search 
yielded 29 publications (including a submission to the National Institute for Health 
and Care Excellence) from which 23 studies were extracted. The studies were mainly 
conducted in US (n= 6), Canada (n= 5), or UK (n= 3). Sample sizes varied from 14 to 
> 8000. Age (mean: 21-47.5 years) was reported in 16 studies while disease duration 
(mean: 2.3-24 years) only in four. Proportion of females ranged between 70-80%. 
Pain and psychiatric disorders were the most common comorbidities. Migraine 
was primarily defined using the International Headache Society’s International 
Classification of Headache Disorders criteria (n= 10). Most studies used validated 
utility instruments: EQ-5D (n= 12), Health Utility Index-Mark 3 (n= 7) or SF-36 (n= 1) 
to assess utility values. Three studies used the Quality of Well Being scale, and two 
used custom questionnaires, using Time Trade Off or Standard Gamble techniques. 
Utilities values were reported using the following categories: by migraine pain sever-
ity (pain-free [0.87-0.96], mild [0.66-0.84], moderate [0.51-0.77] or severe [0.39-0.54]), 
by number of migraine days/month (or percentage reduction in migraine frequency: 
< 50% to ≥ 75% associated with a utility increase: 0.001 to 0.010), or by migraine type 
(chronic [0.43-0.89]/episodic [0.62-0.91]). conclusions: This SLR confirmed that 
increased migraine frequency and pain severity were associated with lower utility 
values among migraineures. A wide range of utility values were reported; potential 
differences across reported estimates are likely due to different populations or dif-
ferent methodologies implemented to derive estimates.
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oBjectives: Treatment Satisfaction Questionnaire for Medication (TSQM) (score 
range 0-100) has been shown to be a reliable and valid instrument to measure 
patients’ satisfaction with their treatment for multiple sclerosis (MS). The 14-item 
TSQM Version1.4 provides scores across four domains: effectiveness, convenience, 
global satisfaction, and side effects. The abbreviated 9-item TQSM-9 excludes the 
side effects domain. Positive changes in score indicate improvement. We conducted 
a systematic review of clinical studies that reported MS patient satisfaction with 
their disease-modifying therapies (DMTs) using TSQM. Methods: We systemati-
cally searched EMBASE, MEDLINE, BIOSIS Previews and Medmeme with pre-specified 
search terms from 2004 onwards for manuscripts and conference proceedings of 
prospective MS studies. The outcomes of interest included study type, change from 
baseline (CFB) in TSQM scores by DMT group, and differences in CFB in TSQM across 
treatment groups. results: Six studies met all study criteria (3 single-arm observa-
tional or surveillance studies and 3 randomized studies). The DMTs studied included 
interferon beta-1b, glatiramer acetate, fingolimod, teriflunomide, and natalizumab. 
Two studies used TSQM Version1.4, while four used TSQM-9. Study length ranged from 
12 weeks to 3 years. CFB at 6 months was the most commonly reported outcome. The 
CFB at 6 months on the effectiveness subscale ranged from 1.8 to 26.9, convenience 
subscale from 3.6 to 41.2, and global satisfaction subscale from 2.9 to 20.4. The CFB 
at 6 months was generally higher for natalizumab and fingolimod compared with 
injectable platform DMTs, although this finding may be confounded by the differ-
ences in study design and patient characteristics. conclusions: Several MS studies 
have used the TSQM to measure patient satisfaction with DMTs. Comparisons across 
identified studies is challenging, as there is substantial heterogeneity with regards to 
version of TSQM used, study type and length, and type of analyses reported.
main contributor to societal costs. Although time on basic and instrumental ADLs 
differed across countries, some of this may be explained by use of community 
care services and institutionalization. Other resources had different patterns of 
use across countries, reflecting country-specific health and social care systems.
NeurologIcal DIsorDers – Patient-reported outcomes & Patient Preference 
studies
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oBjectives: To perform a systematic literature review of adherence to inhaled 
antibiotics for the treatment of chronic Pseudomonas Aeruginosa (PA) infection in 
patients with cystic fibrosis (CF). Methods: A systematic literature search of English-
language articles was conducted in April 2014 using Medline and Embase. No publica-
tion date limit was applied. The literature screening was conducted by 2 independent 
reviewers. All of the included studies were assessed for quality. results: The search 
yielded 192 publications, of which 9 met the inclusion criteria and underwent data 
extraction. Six studies focused on inhaled tobramycin, 1 on inhaled colistimethate, 1 
on inhaled levofloxacin, and 1 on inhaled aztreonam lysine. Medication adherence to 
inhaled antibiotics was analyzed by pharmacy refill history, daily phone diary, parent 
and child self-reports, vials counting, or electronic monitoring. Proportion of adherent 
patients (≥ 75%/80% of required doses taken) in randomized clinical trials (n= 3) ranged 
from 86% to 97%; adherence rates in prospective cohort studies (n= 2) ranged between 
36% and 92%, and in retrospective studies (n= 4) ranged between 60% and 70%. The 
adherence to inhaled antibiotics in CF was found to be associated with the complex-
ity of treatment, time of drug administration, age of patients, treatment burden (i.e., 
adverse events, taste), and patient satisfaction. conclusions: Adherence varied 
depending on the type of study, type of treatment, and method of measurement. In 
real-world trials, poor adherence to inhaled antibiotics was found in patients with CF. 
Regular routine adherence monitoring during CF care, discussion about sub-optimal 
adherence and treatment reinforcement on the basis of treatment burden, clinical 
status, and adverse events may help to better understand the predictors and the 
long-term consequences of non-adherence to inhaled antibiotics for the treatment 
of chronic PA infection in CF.
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oBjectives: Pharmacological management of relapsing-remitting multiple sclerosis 
(RRMS) includes the use of oral, injectable, or infusible Disease Modifying Therapies 
(DMTs). Achieving therapeutic goals in MS requires strict adherence to medication 
administration schedule. To assess compliance and discontinuation rates with DMTs 
in Canadian patients with RRMS. Methods: This non-interventional, retrospec-
tive analysis was based on private claims patient cohorts accessed through IMS Rx 
Dynamics®. Patients had at least one prescription filled for each DMT (oral: fingoli-
mod, dimethyl fumarate (DMF), teriflunomide; injectable (BRACE): interferon beta-1a, 
interferon beta-1b, glatiramer acetate; infusible: natalizumab). Patients were compli-
ant if the medication possession ratio (MPR) was ≥ 80%. Discontinuation rates were 
calculated based on patients who stopped therapy or who were switched to another 
DMT. Compliance and discontinuation rates were collected at 6-month intervals with 
compliance cohorts from August 2011 to December 2014 (rolling 36 months total) and 
discontinuation cohorts from September 2011 to January 2015. results: Compliance 
data was collected for 10315 patients (fingolimod, n= 1524; DMF, n= 1828; terifluno-
mide, n= 456; natalizumab, n= 604; BRACE, n= 5903). Compliance rate across Canada 
was higher for fingolimod (78%) compared to other DMTs, including natalizumab 
(72%), DMF (70%), and BRACE (56%). In Quebec, fingolimod had a compliance rate of 
80%, higher than DMF (68%) and BRACE (65%). Patients on fingolimod had the low-
est discontinuation rate across Canada (22%), compared to natalizumab (30%) and 
BRACE (47%). In Quebec, DMF had a higher discontinuation rate (29%) than other orals 
(fingolimod, 20%; teriflunomide, 23%) and natalizumab (25%). conclusions: In a 
Canadian real-world setting, the compliance rate with fingolimod was higher than 
for other DMTs while the discontinuation rate with fingolimod was lower compared 
to other DMTs. These findings may facilitate MS management strategies which may 
lead to improved clinical and economic outcomes. Findings based in part on data 
licensed from IMS Health Canada Inc. All Rights Reserved.
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oBjectives: To describe the relationship between caregiver health-related quality 
of life (HRQoL), caregiver burden and caregiver time for instrumental activities of 
